This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single indication expansion group assignment study to assess the safety, tolerability, PK, PD, immunogenicity and antitumor activity of MCLA-128. T

MCLA-128

Treatment with anti-cancer medication or investigational drugs within the following intervals before the first dose of MCLA-128:
a. >14 days or >5 half-lives prior to study entry, whichever is shorter.
b. >14 days for radiotherapy. Note: A less than 1-week wash-out period is permitted only for palliative radiation to non-CNS disease with Sponsor approval.

Presence of an active uncontrolled infection or an unexplained fever greater than 38.5°C during Screening up to the first scheduled day of dosing. At the discretion of the Investigator, patients with tumor fever or a clinically insignificant minor infection may be enrolled (i.e., mild upper respiratory infection)

Known symptomatic or unstable brain metastases. Patients with asymptomatic brain metastases are eligible to participate if the metastases have been radiographically and clinically stable for at least one month. If on steroids for this indication, the patient must be on a stable dose for at least one month;